Bruker Corp BRKR
We take great care to ensure that the data presented and summarized in this overview for BRUKER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BRKR
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD13.3MShares$996 Million0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.86MShares$740 Million0.02% of portfolio
-
Black Rock Inc. New York, NY9.71MShares$729 Million0.02% of portfolio
-
Pallas Capital Advisors LLC Braintree, MA9.48MShares$712 Million38.49% of portfolio
-
Massachusetts Financial Services CO Boston, MA8.09MShares$607 Million0.24% of portfolio
-
Rtw Investments, LP New York, NY3.34MShares$251 Million5.04% of portfolio
-
State Street Corp Boston, MA3.25MShares$244 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY2.59MShares$195 Million0.09% of portfolio
-
Invesco Ltd. Atlanta, GA2.09MShares$157 Million0.04% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA2.08MShares$156 Million0.86% of portfolio
Latest Institutional Activity in BRKR
Top Purchases
Top Sells
About BRKR
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Insider Transactions at BRKR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 04
2024
|
Hermann Fritz Requardt |
SELL
Open market or private sale
|
Direct |
15,000
-20.57%
|
$1,335,000
$89.86 P/Share
|
Mar 04
2024
|
Hermann Fritz Requardt |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+17.93%
|
$315,000
$21.08 P/Share
|
Feb 28
2024
|
Falko Busse PRESIDENT, BIOSPIN GROUP |
SELL
Open market or private sale
|
Direct |
28,122
-18.06%
|
$2,390,370
$85.17 P/Share
|
Feb 28
2024
|
Falko Busse PRESIDENT, BIOSPIN GROUP |
BUY
Exercise of conversion of derivative security
|
Direct |
28,122
+11.85%
|
$815,538
$29.5 P/Share
|
Feb 22
2024
|
Burkhard Prause PRES. & CEO, BRUKER BEST |
SELL
Open market or private sale
|
Direct |
15,319
-47.3%
|
$1,271,477
$83.3 P/Share
|
Feb 22
2024
|
Burkhard Prause PRES. & CEO, BRUKER BEST |
BUY
Exercise of conversion of derivative security
|
Direct |
5,450
+4.26%
|
$245,250
$45.37 P/Share
|
Jan 05
2024
|
Philip Ma |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+28.5%
|
-
|
Jan 05
2024
|
Cynthia M Friend |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+14.56%
|
-
|
Jan 05
2024
|
Bob Rosenthal |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+9.31%
|
-
|
Jan 05
2024
|
John A Ornell |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+9.31%
|
-
|
Jan 05
2024
|
Bonnie H Anderson |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+19.16%
|
-
|
Jan 05
2024
|
Richard A Packer |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+3.1%
|
-
|
Jan 05
2024
|
Hermann Fritz Requardt |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+9.31%
|
-
|
Jan 05
2024
|
William A Linton |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+6.29%
|
-
|
Jan 05
2024
|
Adelene Q Perkins |
BUY
Grant, award, or other acquisition
|
Direct |
2,377
+10.03%
|
-
|
Dec 27
2023
|
Juergen Srega PRESIDENT CALID |
SELL
Payment of exercise price or tax liability
|
Direct |
4,840
-3.32%
|
$353,320
$73.63 P/Share
|
Dec 16
2023
|
Frank H Laukien PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,404
-0.0%
|
$102,492
$73.36 P/Share
|
Dec 05
2023
|
William A Linton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.23%
|
$190,000
$19.07 P/Share
|
Oct 26
2023
|
Frank H Laukien PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,523
+0.08%
|
$2,738,058
$46.15 P/Share
|
Aug 11
2023
|
Frank H Laukien PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,421
-0.01%
|
$291,786
$66.96 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 106K shares |
---|---|
Exercise of conversion of derivative security | 231K shares |
Payment of exercise price or tax liability | 35K shares |
---|---|
Open market or private sale | 722K shares |